Stonegate Capital Partners has updated its coverage on Incannex Healthcare Inc. $(IXHL)$ for the third quarter of fiscal year 2025. The company reported a decrease in R&D expenses to $2.74M and SG&A expenses to $2.27M, resulting in a reduced net loss of $3.97M. Cash and cash equivalents increased to $6.7M due to recent financing activities. Incannex will issue ~$24.7M worth of shares to repurchase all outstanding Series A Warrants. More details can be found at newsfilecorp.com/release/167783.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。